» Articles » PMID: 20691883

Penile Cancer--prevention and Premalignant Conditions

Overview
Journal Urology
Specialty Urology
Date 2010 Aug 10
PMID 20691883
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Relatively little evidence is available in the published studies on the prevention of penile cancer and premalignant conditions of the penis. The present review examined the current evidence available in preventing penile cancer and pathologic subtypes of premalignant conditions and their treatment. The recommendations made in the present review formulate the basis of the recent 2009 International Consultation on Urologic Disease Consensus Publishing Group.

Methods: The association of human papillomavirus subtypes and penile cancer is well-established, although the etiology, natural history, and treatment of premalignant lesions have mainly been reported in retrospective case series with short-term follow-up. The exact pathologic role of chronic inflammatory conditions, such as balanitis xerotica obliterans in the etiology of penile cancer remains largely unknown.

Results: Some of the potential strategies for the prevention of penile cancer could include circumcision, reducing the risk of transmission of penile human papillomavirus infection with male vaccination, early treatment of phimosis, smoking cessation, and hygienic measures. Implementing some of these measures would require extensive cost/benefit analysis, with significant changes in the global health policy.

Conclusions: Owing to the current levels of evidence from published studies, firm guidelines cannot be formulated for the treatment of premalignant conditions, although preventative measures, such as reducing human papillomavirus transmission, could become strategic health targets.

Citing Articles

Evidence-Based Recommendations on the Use of Immunotherapies and Monoclonal Antibodies in the Treatment of Male Reproductive Cancers.

Khalid F, Bodla Z, Gaddameedi S, Macasaet R, Yagnik K, Niaz Z Curr Oncol. 2025; 32(2).

PMID: 39996908 PMC: 11854063. DOI: 10.3390/curroncol32020108.


Global research trends in penile cancer: Bibliometric and visualized analysis.

Deng S, Xuan Z, Feng J, Li H, Wang B, Yang Z Front Oncol. 2023; 12:1091816.

PMID: 36686820 PMC: 9853168. DOI: 10.3389/fonc.2022.1091816.


Conversion therapy for advanced penile cancer with tislelizumab combined with chemotherapy: A case report and review of literature.

Long X, Zhang S, Tang L, Li X, Liu J World J Clin Cases. 2022; 10(33):12305-12312.

PMID: 36483823 PMC: 9724507. DOI: 10.12998/wjcc.v10.i33.12305.


Penile Lichen Sclerosis: A Surgical Perspective of its Aetiology and Treatment.

Bhambhani D, Bhambhani S, Pandya N Cureus. 2022; 14(8):e28418.

PMID: 36176860 PMC: 9509524. DOI: 10.7759/cureus.28418.


Prevalence and sequelae of penile lichen sclerosus in males presenting for circumcision in regional Australia: a multicentre retrospective cohort study.

Kwok M, Shugg N, Siriwardana A, Calopedos R, Richards K, Bandi S Transl Androl Urol. 2022; 11(6):780-785.

PMID: 35812204 PMC: 9262734. DOI: 10.21037/tau-22-29.